Abstract | OBJECTIVES: METHODS: A total of 12 patients with bipolar I or II depression entered this pilot, proof-of-concept eight-week investigation and 10 returned for at least one post-baseline visit. They were initiated on isradipine at 2.5 mg and titrated up to 10 mg daily, with blinded assessments of depression using the Montgomery-Åsberg Depression Rating Scale (MADRS) as well as adverse effects. RESULTS: Among the 10 patients, three had bipolar II disorder; all but two reported current episode duration longer than six months. In all, four of 10 completed the study; no significant adverse events were observed, although one subject discontinued treatment per protocol because of possible hypomanic symptoms which had resolved prior to study visit. In a mixed-effects model, mean improvement in depression severity, assessed by MADRS, was 2.1 (standard error = 0.36) points/week (p < 0.001). Two of the 10 subjects remitted and four of the 10 subjects experienced 50% or greater symptomatic improvement with treatment. CONCLUSIONS:
Isradipine merits further investigation for the treatment of bipolar depression. This preliminary trial illustrates the potential utility of genetic investigation in identifying psychiatric treatment targets.
|
Authors | Michael J Ostacher, Dan V Iosifescu, Aleena Hay, Sarah R Blumenthal, Pamela Sklar, Roy H Perlis |
Journal | Bipolar disorders
(Bipolar Disord)
Vol. 16
Issue 2
Pg. 199-203
(Mar 2014)
ISSN: 1399-5618 [Electronic] Denmark |
PMID | 24372835
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
Chemical References |
- Calcium Channel Blockers
- Calcium Channels, L-Type
- Isradipine
|
Topics |
- Adult
- Bipolar Disorder
(drug therapy)
- Calcium Channel Blockers
(therapeutic use)
- Calcium Channels, L-Type
(genetics)
- Female
- Genome-Wide Association Study
- Humans
- Isradipine
(therapeutic use)
- Male
- Middle Aged
- Pilot Projects
- Psychiatric Status Rating Scales
|